Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Ascentage Pharma (Suzhou) Co., Ltd.

5 abstracts

Abstract
Updated efficacy results of olverembatinib (HQP1351) in patients with tyrosine kinase inhibitor (TKI)-resistant succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) and paraganglioma.
Org: Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Fudan University Shanghai Cancer Center, The Affliated Cancer Hospital of Zhengzhou University,
Abstract
FAK inhibition with novel FAK/ALK inhibitor APG-2449 could overcome resistance in NSCLC patients who are resistant to second-generation ALK inhibitors.
Org: Sun Yat-sen University Cancer Center Gansu Hospital, Hunan Provincial Oncology Hospital, Zhejiang Cancer Hospital, Chinese Academy of Sciences, Respiratory Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China,
Abstract
Preliminary data of a phase 1b/2 study of BCL-2 inhibitor lisaftoclax (APG-2575) alone or combined with ibrutinib or rituximab in patients (pts) with Waldenström macroglobulinemia (WM).
Org: Ascentage Pharma (Suzhou) Co., Ltd., Ascentage Pharma Group, Jiangsu Ascentage Pharma Pty Ltd.,
Abstract
Antitumor activity of olverembatinib (HQP1351) in patients (pts) with tyrosine kinase inhibitor (TKI)–resistant succinate dehydrogenase (SDH)–deficient gastrointestinal stromal tumor (GIST).
Org: Fudan University Shanghai Cancer Center, Henan Cancer Hospital, Union Hospital Medical College Huazhong University of Science and Technology, Guangdong Provincial People's Hospital, Chinese People’s Liberation Army General Hospital,
Abstract
A phase 2 study of alrizomadlin, a novel MDM2/p53 inhibitor, in combination with pembrolizumab for treatment of patients with malignant peripheral nerve sheath tumor (MPNST).
Org: Ascentage Pharma Group, Ascentage Pharma (Suzhou) Co., Ltd., State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center Gansu Hospital,